Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001883728 | SCV002147225 | uncertain significance | Hereditary hyperekplexia | 2021-04-23 | criteria provided, single submitter | clinical testing | Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt GLRA1 protein function. This sequence change replaces histidine with asparagine at codon 447 of the GLRA1 protein (p.His447Asn). The histidine residue is moderately conserved and there is a small physicochemical difference between histidine and asparagine. This variant is present in population databases (rs146481873, ExAC 0.002%). This variant has not been reported in the literature in individuals with GLRA1-related conditions. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Génétique des Maladies du Développement, |
RCV004556089 | SCV005045219 | likely pathogenic | Seizure | 2024-05-22 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004980853 | SCV005591780 | uncertain significance | Inborn genetic diseases | 2024-08-01 | criteria provided, single submitter | clinical testing | The c.1339C>A (p.H447N) alteration is located in exon 9 (coding exon 9) of the GLRA1 gene. This alteration results from a C to A substitution at nucleotide position 1339, causing the histidine (H) at amino acid position 447 to be replaced by an asparagine (N). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |